Local radiotherapy for palliation in multiple myeloma patients with symptomatic bone lesions.
- Author:
Jeong Won LEE
1
;
Jeong Eun LEE
Author Information
- Publication Type:Original Article
- Keywords: Multiple myeloma; Bone; Radiotherapy; Palliative therapy
- MeSH: Drug Therapy; Follow-Up Studies; Humans; Multiple Myeloma*; Palliative Care; Radiotherapy*
- From:Radiation Oncology Journal 2016;34(1):59-63
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: To evaluate the clinical outcomes of symptomatic bone lesions in patients with multiple myeloma (MM) who received local radiotherapy (LRT). MATERIALS AND METHODS: Fifty-one patients with 87 symptomatic bone lesions treated via LRT were analyzed. LRT was delivered at a median total dose of 21 Gy (range, 12 to 40 Gy) in a median of 7 fractions (range, 4 to 20 fractions). The clinical outcomes of LRT and the factors affecting treatment response were assessed. RESULTS: After a median follow-up time of 66.7 weeks, symptom relief was achieved for 85 of 87 lesions (97.7%). The median time to symptom relief was 7 days from the start of LRT (range, 1 to 67 days). The duration of in-field failure-free survival ranged from 1.1 to 450.9 weeks (median, 66.7 weeks). The radiation dose or use of previous and concurrent chemotherapy was not significantly associated with in-field failure for LRT (p = 0.354, 0.758, and 0.758, respectively). CONCLUSION: Symptomatic bone lesions in patients with MM can be successfully treated with LRT. A higher radiation dose or the use of concurrent chemotherapy may not influence the in-field disease control. A relatively low radiation dose could achieve remission of symptoms in patients with MM.
